Nifty
Sensex
:
:
25843.15
84363.37
133.30 (0.52%)
411.18 (0.49%)

Pharmaceuticals & Drugs - Global

Rating :
66/99

BSE: 500257 | NSE: LUPIN

1943.80
20-Oct-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1954
  •  1964
  •  1936.9
  •  1940.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  882938
  •  1717751178.8
  •  2402.9
  •  1795.2

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 88,830.84
  • 23.94
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 90,765.16
  • 0.62%
  • 4.83

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.90%
  • 0.24%
  • 5.12%
  • FII
  • DII
  • Others
  • 20.5%
  • 25.01%
  • 2.23%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.85
  • 8.41
  • 10.92

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.66
  • 15.51
  • 25.13

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.82
  • 21.98
  • 96.87

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 30.34
  • 35.92
  • 40.92

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.60
  • 4.09
  • 4.69

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.44
  • 18.17
  • 18.96

Earnings Forecasts:

(Updated: 18-10-2025)
Description
2024
2025
2026
2027
Adj EPS
71.95
89.91
88.03
94
P/E Ratio
27.02
21.62
22.08
20.68
Revenue
22192.1
25283.2
26728.1
28386.7
EBITDA
5277.52
6343.1
6331.36
6640.92
Net Income
3281.62
4108.37
4002.68
4209.82
ROA
12.34
14.19
12.61
12.37
P/B Ratio
5.16
4.27
3.66
3.23
ROE
20.84
21.42
17.71
16.63
FCFF
1192.22
3354.57
3626.68
3665.89
FCFF Yield
1.28
3.59
3.88
3.92
Net Debt
2844.97
-1682.34
-4866.46
-7028.1
BVPS
376.8
454.86
530.96
602.01

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Net Sales
6,268.34
5,600.33
11.93%
5,667.13
4,960.79
14.24%
5,767.71
5,197.41
10.97%
5,672.73
5,038.56
12.59%
Expenses
4,541.10
4,359.36
4.17%
4,345.96
3,963.94
9.64%
4,411.81
4,159.47
6.07%
4,332.37
4,120.80
5.13%
EBITDA
1,727.24
1,240.97
39.18%
1,321.17
996.85
32.53%
1,355.90
1,037.94
30.63%
1,340.36
917.76
46.05%
EBIDTM
27.55%
22.16%
23.31%
20.09%
23.51%
19.97%
23.63%
18.21%
Other Income
79.04
67.78
16.61%
56.95
29.25
94.70%
53.71
29.37
82.87%
42.29
40.40
4.68%
Interest
91.76
68.01
34.92%
89.10
71.29
24.98%
66.89
74.01
-9.62%
70.87
80.64
-12.12%
Depreciation
298.98
247.71
20.70%
393.18
457.10
-13.98%
271.45
257.20
5.54%
256.92
247.85
3.66%
PBT
1,415.54
993.03
42.55%
895.84
497.71
79.99%
1,071.27
736.10
45.53%
1,054.86
629.67
67.53%
Tax
194.08
187.49
3.51%
113.46
129.49
-12.38%
212.41
117.40
80.93%
195.38
134.35
45.43%
PAT
1,221.46
805.54
51.63%
782.38
368.22
112.48%
858.86
618.70
38.82%
859.48
495.32
73.52%
PATM
19.49%
14.38%
13.81%
7.42%
14.89%
11.90%
15.15%
9.83%
EPS
26.69
17.57
51.91%
16.92
7.89
114.45%
18.74
13.46
39.23%
18.69
10.76
73.70%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
23,375.91
22,707.90
20,010.82
16,641.66
16,405.48
15,162.96
16,836.56
16,751.37
15,804.15
17,494.33
14,139.03
Net Sales Growth
12.40%
13.48%
20.25%
1.44%
8.19%
-9.94%
0.51%
5.99%
-9.66%
23.73%
 
Cost Of Goods Sold
6,869.62
5,818.18
5,644.66
6,023.89
5,780.84
4,854.28
4,962.72
4,436.67
4,733.76
4,660.97
3,893.70
Gross Profit
16,506.29
16,889.72
14,366.16
10,617.77
10,624.64
10,308.68
11,873.84
12,314.70
11,070.39
12,833.36
10,245.33
GP Margin
70.61%
74.38%
71.79%
63.80%
64.76%
67.99%
70.52%
73.51%
70.05%
73.36%
72.46%
Total Expenditure
17,631.24
17,430.38
16,221.71
14,921.09
16,190.24
12,596.08
14,362.21
14,082.44
12,656.64
13,001.19
10,453.68
Power & Fuel Cost
-
479.09
493.07
479.68
443.96
414.48
443.17
442.28
433.88
377.86
381.27
% Of Sales
-
2.11%
2.46%
2.88%
2.71%
2.73%
2.63%
2.64%
2.75%
2.16%
2.70%
Employee Cost
-
3,964.20
3,494.57
3,087.15
2,989.30
2,825.90
2,986.84
2,770.17
2,864.71
2,849.52
2,141.62
% Of Sales
-
17.46%
17.46%
18.55%
18.22%
18.64%
17.74%
16.54%
18.13%
16.29%
15.15%
Manufacturing Exp.
-
3,006.40
2,738.39
2,176.13
2,187.99
1,945.67
1,852.21
1,731.57
2,087.52
2,270.19
1,766.00
% Of Sales
-
13.24%
13.68%
13.08%
13.34%
12.83%
11.00%
10.34%
13.21%
12.98%
12.49%
General & Admin Exp.
-
2,514.00
2,221.05
1,733.07
3,490.62
1,218.42
1,456.46
3,302.60
1,219.96
1,509.56
1,195.98
% Of Sales
-
11.07%
11.10%
10.41%
21.28%
8.04%
8.65%
19.72%
7.72%
8.63%
8.46%
Selling & Distn. Exp.
-
1,417.19
1,343.30
1,188.72
1,096.10
1,026.40
1,080.45
1,206.60
1,150.61
1,049.48
870.29
% Of Sales
-
6.24%
6.71%
7.14%
6.68%
6.77%
6.42%
7.20%
7.28%
6.00%
6.16%
Miscellaneous Exp.
-
231.32
286.67
232.45
201.43
310.93
1,580.36
192.55
166.20
283.61
870.29
% Of Sales
-
1.02%
1.43%
1.40%
1.23%
2.05%
9.39%
1.15%
1.05%
1.62%
1.45%
EBITDA
5,744.67
5,277.52
3,789.11
1,720.57
215.24
2,566.88
2,474.35
2,668.93
3,147.51
4,493.14
3,685.35
EBITDA Margin
24.58%
23.24%
18.94%
10.34%
1.31%
16.93%
14.70%
15.93%
19.92%
25.68%
26.07%
Other Income
231.99
201.61
141.58
150.91
213.67
136.29
483.76
333.01
150.35
106.51
185.19
Interest
318.62
294.87
311.61
274.30
142.77
140.64
362.98
302.49
204.35
152.53
59.47
Depreciation
1,220.53
1,169.26
1,196.81
880.69
1,658.71
887.41
970.22
846.05
1,085.87
912.23
487.13
PBT
4,437.51
4,015.00
2,422.27
716.49
-1,372.57
1,675.12
1,624.91
1,853.40
2,007.64
3,534.89
3,323.94
Tax
715.33
708.74
486.70
268.80
137.15
448.52
1,146.56
901.69
288.46
978.51
1,059.34
Tax Rate
16.12%
17.65%
20.09%
37.52%
-9.99%
26.78%
131.36%
59.58%
53.10%
27.68%
31.87%
PAT
3,722.18
3,281.62
1,914.48
430.08
-1,528.04
1,215.20
-273.72
611.73
247.74
2,549.21
2,255.84
PAT before Minority Interest
3,699.34
3,306.26
1,935.57
447.69
-1,509.36
1,226.60
-273.72
611.73
254.83
2,556.38
2,264.60
Minority Interest
-22.84
-24.64
-21.09
-17.61
-18.68
-11.40
0.00
0.00
-7.09
-7.17
-8.76
PAT Margin
15.92%
14.45%
9.57%
2.58%
-9.31%
8.01%
-1.63%
3.65%
1.57%
14.57%
15.95%
PAT Growth
62.70%
71.41%
345.15%
-
-
-
-
146.92%
-90.28%
13.00%
 
EPS
81.48
71.84
41.91
9.42
-33.45
26.60
-5.99
13.39
5.42
55.81
49.38

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
17,203.50
14,290.29
12,464.50
12,153.27
13,803.14
12,536.70
13,742.23
13,577.06
13,497.57
11,163.37
Share Capital
91.32
91.14
91.00
90.90
90.74
90.60
90.50
90.42
90.32
90.12
Total Reserves
17,028.20
14,084.70
12,224.56
11,900.64
13,522.87
12,231.40
13,433.31
13,275.26
13,233.50
10,958.87
Non-Current Liabilities
2,390.04
819.70
992.09
1,153.07
1,136.03
3,003.18
7,296.41
6,876.13
6,446.96
6,032.39
Secured Loans
1,196.48
0.00
0.00
141.86
0.33
0.70
358.82
448.03
217.15
5.55
Unsecured Loans
569.75
0.00
27.51
0.00
15.79
1,792.58
6,282.90
5,976.47
5,430.63
5,368.35
Long Term Provisions
436.08
375.40
343.03
332.99
329.49
296.29
370.79
356.85
308.73
190.00
Current Liabilities
8,961.39
8,501.50
9,265.37
8,276.44
8,436.09
9,225.20
6,129.87
5,095.55
6,120.59
5,061.17
Trade Payables
2,958.16
2,958.11
2,531.53
2,282.91
2,014.44
2,412.30
2,498.18
2,575.40
2,588.90
1,988.82
Other Current Liabilities
2,274.32
1,919.40
1,577.22
1,394.11
2,766.67
3,124.23
1,279.82
1,517.16
657.97
1,001.27
Short Term Borrowings
3,015.56
2,669.91
4,216.54
3,702.30
3,049.44
2,492.75
1,580.21
451.76
2,304.33
1,745.41
Short Term Provisions
713.35
954.08
940.08
897.12
605.54
1,195.92
771.66
551.23
569.39
325.67
Total Liabilities
28,645.78
23,694.65
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
Net Block
9,719.35
8,878.30
8,355.24
7,381.62
7,880.76
7,938.11
11,086.71
10,361.99
11,032.93
8,716.96
Gross Block
20,183.69
19,664.69
18,077.42
15,990.30
14,726.75
14,160.50
15,731.88
13,859.86
12,395.30
9,212.07
Accumulated Depreciation
10,406.26
10,653.98
9,722.18
8,608.68
6,845.99
6,222.39
4,645.17
3,497.87
1,362.37
495.11
Non Current Assets
11,847.20
10,247.00
10,348.98
9,193.81
9,443.86
9,396.33
13,361.79
13,379.28
14,146.71
12,401.61
Capital Work in Progress
516.64
772.53
1,237.99
1,146.28
1,066.26
939.62
1,639.71
2,598.20
2,133.06
2,702.40
Non Current Investment
87.27
227.70
77.13
77.60
78.07
36.07
185.63
26.71
22.00
14.33
Long Term Loans & Adv.
307.83
320.65
620.92
572.41
405.79
409.58
402.61
383.00
950.76
960.22
Other Non Current Assets
1,216.11
47.82
57.70
15.90
12.98
72.95
47.13
9.38
7.96
7.70
Current Assets
16,798.58
13,447.65
12,451.30
12,457.68
13,986.37
15,413.21
13,853.58
12,209.54
11,952.93
9,887.40
Current Investments
1,059.11
846.93
439.77
822.40
2,376.81
2,338.25
2,109.86
234.86
2,114.13
2.02
Inventories
5,476.35
4,953.90
4,491.76
4,630.73
4,092.01
3,456.87
3,836.77
3,662.49
3,642.28
3,273.65
Sundry Debtors
5,497.10
4,692.05
4,480.70
4,261.94
4,474.32
5,445.93
5,149.80
5,192.21
4,307.34
4,548.76
Cash & Bank
3,142.33
1,202.54
1,293.13
1,098.13
1,742.46
2,454.30
987.20
1,408.03
698.17
821.75
Other Current Assets
1,623.69
1,428.05
1,519.98
497.54
1,300.77
1,717.86
1,769.95
1,711.95
1,191.01
1,241.22
Short Term Loans & Adv.
312.63
324.18
225.96
1,146.94
743.88
1,180.53
992.48
1,090.65
657.58
761.78
Net Current Assets
7,837.19
4,946.15
3,185.93
4,181.24
5,550.28
6,188.01
7,723.71
7,113.99
5,832.34
4,826.23
Total Assets
28,645.78
23,694.65
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
2,999.94
3,648.36
1,897.24
367.31
1,821.76
1,468.84
1,665.97
1,751.19
4,113.51
-382.39
PBT
4,015.00
2,422.27
716.49
-1,372.21
1,676.45
876.78
1,517.17
546.81
3,543.14
3,328.84
Adjustment
1,301.52
1,466.63
1,097.41
1,707.68
1,033.16
1,574.29
1,588.41
2,782.23
1,214.74
585.35
Changes in Working Capital
-1,410.54
85.51
326.52
-15.04
-192.49
-471.02
-500.19
-1,019.43
504.62
-3,126.44
Cash after chg. in Working capital
3,905.98
3,974.41
2,140.42
320.43
2,517.12
1,980.05
2,605.39
2,309.61
5,262.50
787.75
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-906.04
-326.05
-243.18
46.88
-695.36
-511.21
-939.42
-558.42
-1,148.99
-1,170.14
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-4,171.89
-1,712.20
-1,286.77
1,292.23
-1,239.58
1,106.99
-3,282.47
469.87
-2,527.44
-6,961.71
Net Fixed Assets
-900.14
283.80
-682.44
-471.44
-693.00
-481.49
-462.56
-1,394.31
-876.24
480.96
Net Investments
-374.36
-1,606.34
-463.24
51.49
-2,106.15
-67.96
-2,025.62
1,551.07
-3,173.10
-296.59
Others
-2,897.39
-389.66
-141.09
1,712.18
1,559.57
1,656.44
-794.29
313.11
1,521.90
-7,146.08
Cash from Financing Activity
1,731.88
-2,184.21
-337.25
-1,572.32
-1,885.27
-890.58
744.13
-1,492.10
433.18
5,836.38
Net Cash Inflow / Outflow
559.93
-248.05
273.22
87.22
-1,303.09
1,685.25
-872.37
728.96
2,019.25
-1,507.72
Opening Cash & Equivalents
983.76
1,231.81
991.37
926.22
2,229.31
544.06
1,416.43
687.47
780.22
2,095.06
Closing Cash & Equivalent
1,543.69
983.76
1,264.59
1,013.44
926.22
2,229.31
544.06
1,416.43
2,799.47
780.22

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
374.93
311.08
270.67
263.84
300.06
272.01
298.87
295.64
295.04
245.21
ROA
12.63%
8.33%
2.01%
-6.70%
5.09%
-1.05%
2.32%
0.99%
10.57%
12.82%
ROE
21.13%
14.61%
3.68%
-11.79%
9.46%
-2.12%
4.55%
1.91%
20.98%
22.80%
ROCE
21.97%
16.24%
6.06%
-7.11%
9.70%
6.02%
8.45%
3.54%
18.53%
24.38%
Fixed Asset Turnover
1.87
1.68
1.67
1.93
1.96
2.10
1.93
2.07
1.63
1.80
Receivable days
50.00
52.75
56.09
53.73
64.06
61.62
66.11
63.76
91.82
92.24
Inventory Days
51.19
54.32
58.53
53.64
48.75
42.41
47.94
49.03
71.70
73.96
Payable days
185.58
177.49
144.07
132.55
161.68
65.89
68.49
68.56
60.60
63.20
Cash Conversion Cycle
-84.38
-70.43
-29.45
-25.18
-48.88
38.14
45.56
44.23
102.92
103.00
Total Debt/Equity
0.30
0.19
0.34
0.32
0.35
0.51
0.63
0.53
0.60
0.65
Interest Cover
14.62
8.77
3.61
-8.61
12.91
3.40
6.00
3.66
24.18
56.89

News Update:


  • USFDA conducts pre-approval inspection at Lupin’s Somerset facility
    11th Oct 2025, 15:26 PM

    The Inspection was conducted from September 29, 2025 to October 10, 2025, and concluded with one observation

    Read More
  • Lupin planning to set up pharmaceutical manufacturing plant in Florida
    9th Oct 2025, 12:59 PM

    The projected cumulative investment for the plant is $250 million

    Read More
  • USFDA classifies Lupin's Pithampur Unit-2 inspection as OAI
    6th Oct 2025, 10:59 AM

    The inspection undertaken by USFDA at Lupin’s Pithampur Unit-2 manufacturing facility from July 8 to July 17, 2025

    Read More
  • Lupin launches Liraglutide Injection in US
    4th Oct 2025, 10:24 AM

    It is indicated as an adjunct to diet and exercise to improve glycemic control in adults

    Read More
  • Lupin launches Rivaroxaban for Oral Suspension in US
    1st Oct 2025, 16:58 PM

    Rivaroxaban for Oral Suspension, 1 mg/mL is bioequivalent to Xarelto for Oral Suspension, 1 mg/mL of Janssen Pharmaceuticals, Inc

    Read More
  • Lupin receives USFDA's approval for Rivaroxaban for Oral Suspension
    1st Oct 2025, 09:05 AM

    The product will be manufactured at the company's Chhatrapati Sambhajinagar facility in India

    Read More
  • Lupin’s arm signs definitive agreement to acquire VISUfarma B.V.
    29th Sep 2025, 09:27 AM

    The transaction is projected to close by the end of 2025, subject to certain closing conditions

    Read More
  • Lupin gets tentative nod for Bictegravir, Emtricitabine, Tenofovir Alafenamide Tablets
    24th Sep 2025, 17:29 PM

    This product would be manufactured at Lupin’s Nagpur facility in India

    Read More
  • USFDA conducts pre-approval inspection at Lupin’s Pune Biotech facility
    20th Sep 2025, 17:18 PM

    The inspection closed with four observations

    Read More
  • Lupin receives U.S. FDA's approval for Lenalidomide Capsules
    17th Sep 2025, 17:52 PM

    The product will be manufactured at company’s Pithampur facility in India

    Read More
  • USFDA concludes inspection at Lupin’s Nagpur Injectable facility
    17th Sep 2025, 10:12 AM

    The inspection closed with six observations

    Read More
  • USFDA concludes PAI at Lupin’s Aurangabad facility
    6th Sep 2025, 10:38 AM

    The inspection closed with two observations

    Read More
  • Lupin gets USFDA’s nod for Risperidone injectable
    3rd Sep 2025, 16:58 PM

    This is the company’s first product using proprietary Nanomi B.V.’s (Nanomi) technology and has a 180-day CGT exclusivity

    Read More
  • Lupin launches Bosentan Tablets for Oral Suspension in United States
    20th Aug 2025, 11:00 AM

    NATCO holds the exclusive first-to-file status for this product and will have 180-day generic drug exclusivity

    Read More
  • Lupin partners with Sandoz Group AG
    12th Aug 2025, 14:40 PM

    The partnership is to market and commercialize Lupin’s biosimilar ranibizumab across multiple regions

    Read More
  • Lupin launches Glucagon for Injection USP, 1mg/vial in United States
    11th Aug 2025, 11:50 AM

    Glucagon for Injection USP, 1mg/vial packaged in an emergency kit had an estimated annual sale of $122 million in the U.S.

    Read More
  • Lupin reports 52% rise in Q1 consolidated net profit
    6th Aug 2025, 12:16 PM

    The total consolidated income of the company increased by 11.98% at Rs 6347.38 crore for Q1FY26

    Read More
  • Lupin - Quarterly Results
    5th Aug 2025, 20:40 PM

    Read More
  • Lupin gets USFDA’s nod for Liraglutide and Glucagon Injectable Products
    24th Jul 2025, 14:30 PM

    Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India

    Read More
  • USFDA concludes inspection at Lupin’s Pithampur Unit-2 manufacturing facility
    18th Jul 2025, 12:59 PM

    The inspection closed with the issuance of a Form-483 with four observations

    Read More
  • Lupin’s arm receives GMP certification from Therapeutic Goods Administration
    18th Jul 2025, 11:19 AM

    LMS offers pharmaceutical CDMO services and is engaged in the manufacturing and supply of APIs

    Read More
  • USFDA concludes inspection at Lupin’s Pithampur unit 3 manufacturing facility
    18th Jul 2025, 10:22 AM

    The inspection closed with the issuance of a Form-483 with three observations

    Read More
  • Lupin launches Loteprednol Etabonate Ophthalmic Suspension in United States
    16th Jul 2025, 18:34 PM

    Loteprednol Etabonate Ophthalmic Suspension, 0.5% is bioequivalent to Lotemax Ophthalmic Suspension, 0.5%, of Bausch & Lomb Inc

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.